Ironwood Pharmaceuticals (IRWD) Net Income towards Common Stockholders (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Net Income towards Common Stockholders data on file, last reported at $40.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 209.06% year-over-year to $40.8 million; the trailing twelve-month figure through Mar 2026 stood at -$59.0 million (down 149.05% YoY), and the FY2025 full-year result was -$137.1 million, down 189.39% from the prior year.
• Net Income towards Common Stockholders rose to $40.8 million in Q1 2026, from -$163.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $154.8 million in Q4 2024 to a low of -$1.1 billion in Q2 2023.
• A 5-year average of -$50.9 million and a median of $23.6 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 3038.3% in 2023 and surged 2844.07% in 2025, its largest moves.
• Tracing IRWD's Net Income towards Common Stockholders over 5 years: stood at $126.5 million in 2022, then sank by 215.0% to -$145.5 million in 2023, then jumped by 206.4% to $154.8 million in 2024, then sank by 205.57% to -$163.4 million in 2025, then surged by 124.95% to $40.8 million in 2026.
• Business Quant data shows IRWD's Net Income towards Common Stockholders at $40.8 million in Q1 2026, -$163.4 million in Q4 2025, and $40.1 million in Q3 2025.